Abstract
Idiopathic dilated cardiomyopathy (DCM) is a life-threatening heart disease and a major reason for heart transplantations. The medical efficacy of immunoadsorption (IA) for DCM patients has been demonstrated in initial clinical studies. This prospective matched-case control study examined 5-year survival rates, direct medical costs, and cost-effectiveness in Germany (n=34) from a health-care system perspective. In a cost-effectiveness analysis costs per life year gained were calculated. Patients treated with IA showed a greater survival rate: 5-year survival rate in the intervention group was 82% vs. 41% in controls. Log rank statistics after Kaplan-Meier analysis of cumulated survival probability were highly significant. Initial intervention costs for IA were found to be €28,400 per patient treated. Direct medical costs for a 5-year follow-up were €128,600 per patient treated with IA and €75,500 in controls. Considering only the actual survival time we calculated annual treatment costs of €24,900 in the IA group and €28,900 in controls. The cost-effectiveness ratio expressed in costs per life year gained was €34,400. This is the first controlled study to perform 5-year survival analysis and economic evaluation of this new emerging technology for patients with DCM. Although high initial treatment costs for IA are incurred, the significantly better survival rates lead to reasonable costs per live year gained.
Similar content being viewed by others
References
Bland JM, Altman DG (1998) Survival probabilities (the Kaplan-Meier method). BMJ 317:1572
CCOHTA (1996) A guidance document for the costing process. CCOHTA: Ottawa
CCOHTA (1997) Guidelines for economic evaluation of pharmaceuticals: Canada, 2nd edn. CCOHTA: Ottawa
Dec GW, Fuster V (1994) Idiopathic dilated cardiomyopathy—review article. N Engl J Med 331:1564–1575
Drummond MF, O'Brien BJ, Stoddart GL, Torrance GW (1997) Methods for the economic evaluation of health care programmes. Oxford University Press: Oxford
Feldman AM, McNamara DM (2000) Myocarditis. N Engl J Med 343:1388–1398
Felix SB, Staudt A, Dorffel WV, Stangl V, Merkel K, Pohl M, Docke WD, Morgera S, Neumayer HH, Wernecke KD, Wallukat G, Stangl K, Baumann G (2000) Hemodynamic effects of immunoadsorption and subsequent immunoglobulin substitution in dilated cardiomyopathy: three-month results from a randomized study. J Am Coll Cardiol 35:1590–1598
Gold MR, Siegel JE, Russell LB, Weinstein MC (1996) Cost-effectiveness in health and medicine. Oxford University Press: Oxford
Gruppe HK (1999) Empfehlungen zur gesundheitsökonomischen Evaluation—revidierte Fassung des Hannoveraner Konsens. Gesundheitsokon Qualitatsmanage 4:A62–A65
Hessel FP, Kohlmann T, Krauth C, Nowy R, Seitz R, Siebert U, Wasem J (1999) Ökonomische Evaluation in der Rehabiliation: Prinzipien und Empfehlungen für die Leistungserfassung. DRV-Schriften 16:103–246
Hirth RA, Chernow ME, Miller E, Fendrick AM, Weissert WG (2000) Willingness to pay for a quality adjusted life year: In search of a standard. Med Decis Making 20:332–342
Hobbs FD, Kenkre, JE, Roalfe AK, Davis RC, Hare R, Davis MK (2002) Impact of heart failure and left ventricular systolic dysfunction on quality of life: a cross-sectional study comparing common chronic cardiac and medical disorders and a representative adult population. Eur Heart J 23:1867–1876
Hosenpud JD, Bennett LE, Keck BM, Fiol B, Novick RJ (1997) The registry of the International Society for Heart and Lung Transplantation. Fourteenth official report 1997. J Heart Lung Transplant 16:691–712
Jünger J, Schellberg D, Kraemer S, Haunstetter A, Zugck C, Herzog W, Haass M (2002) Health related quality of life in patients with congestive heart failure: comparison with other chronic diseases and relation to functional variables. Heart 87:235–241
Mann DL (2001) Autoimmunity, immunoglobulin adsorption and dilated cardiomyopathy: has the time come for randomized clinical trials? J Am Coll Cardiol 38:184–186
Muller J, Wallukat G, Dandel M, Bieda H, Brandes K, Spiegelsberger S, Nissen E, Kunze R, Hetzer R (2000) Immunoglobulin adsorption in patients with idiopathic dilated cardiomyopathy. Circulation 101:385–391
Richardson P, McKenna W, Bristow M, Maisch B, Mautner B, O'Connell J, Olsen E, Thiene G, Goodwin J, Gyarfas I, Martin I, Nordet P (1996) Report of the 1995 World Health Organization/International Society and Federation of Cardiology Task Force on the Definition and Classification of Cardiomyopathies. Circulation 93:841–842
Schimke I, Muller J, Priem F, Kruse I, Schon B, Stein J, Kunze R, Wallukat G, Hetzer R (2001) Decreased oxidative stress in patients with idiopathic dilated cardiomyopathy one year after immunoglobulin adsorption. J Am Coll Cardiol 38:178–183
Tamburro P, Wilber D (1992) Sudden death in idiopathic dilated cardiomyopathy. Am Heart J 124:1035–1045
Acknowledgements
This study was supported in part by PlasmaSelect AG, Teterow, Germany.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Hessel, F.P., Wegner, C., Müller, J. et al. Economic evaluation and survival analysis of immunoglobulin adsorption in patients with idiopathic dilated cardiomyopathy. HEPAC 5, 58–63 (2004). https://doi.org/10.1007/s10198-003-0202-5
Issue Date:
DOI: https://doi.org/10.1007/s10198-003-0202-5